ANDIS is a combined research and quality assurance project with the long term aim of introducing precision medicine in diabetes. In connection with a visit to your doctor or diabetes nurse personal identification number, name, address, date of diagnosis, initial and current diabetes treatment, time of start of diabetes treatment, weight and height, possible diabetes during pregnancy, information on the prevalence of diabetes in the family as well as information about the country of birth of the study person and his/her parents was registered. Upon registration, blood samples for determination of GAD antibodies and C-peptide as well as for DNA analysis are taken. The DNA sample is used to classify the disease into subtypes, and to investigate hereditary causes of diabetes, diabetic complications and other medical conditions associated with diabetes. One blood sample is stored for possible future analysis. If the study person previously have given consent for registration of his or her data in the National Diabetes Register (NDR) the study person is asked whether this information can be linked to the ANDIS database on an annual basis. The ANDIS registry is also linked with the Region Skåne Care Database and the register for prescribed drugs to add information about the use of medications and diabetic complications. Ongoing study, currently> 11,000 patients (January 2015). Purpose: To register all new cases of diabetes in Scania and improve diagnosis and treatment strategies. The cohort cover the full spectrum of diabetes in Region Skåne. It has unique representation since a majority of all health care providers, hospitals and clinics participate.
Institutionen för kliniska vetenskaper, avdelningen för diabetes och endokrinologi
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
The systematic arrangement of entities in any field into categories classes based on common characteristics such as properties, morphology, subject matter, etc.
The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles.
The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
documentation/Etiskt tillstånd ANDIS.pdf
documentation/Patient info ANDIS 2011_sv.pdf